Juno Therapeutics (JUNO) Tops Q1 EPS by 4c

Juno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34).

Strong quarter-end cash position of$447.6 million.

Affirmed 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and now-settled litigation.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Salem Media Group (SALM) Reports Q2 Loss of $0.11
• Nauticus Robotics (KITT) Reports Q2 Loss of $2.30